SEC Comment Letter for Milestone Pharmaceuticals (MIST) — May 18, 2026
Milestone Pharmaceuticals Inc.
Date: May 18, 2026 · CIK: 0001408443 · Accession: 0000000000-26-005086
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295860
Letter
Re: Milestone Pharmaceuticals Inc. Registration Statement on Form S-3 Filed May 13, 2026 File No. 333-295860 Dear Joseph Oliveto: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions.
May 18, 2026
Joseph Oliveto Chief Executive Officer Milestone Pharmaceuticals Inc. 6210 Ardrey Kell Road, Suite 650 Charlotte, NC 28277
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ryan Sansom, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 18, 2026 Joseph Oliveto Chief Executive Officer Milestone Pharmaceuticals Inc. 6210 Ardrey Kell Road, Suite 650 Charlotte, NC 28277 Re: Milestone Pharmaceuticals Inc. Registration Statement on Form S-3 Filed May 13, 2026 File No. 333-295860 Dear Joseph Oliveto: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Sansom, Esq. </TEXT> </DOCUMENT>